Nurix Therapeutics Inc stock is traded under the ticker #NRIX. Below you can review Nurix Therapeutics Inc stock performance in the past 12 months up to November 2025

Total visits to Nurix Therapeutics Inc's top domains

Understand Nurix Therapeutics Inc market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

nurixtx.com45K

See more with Sales Intelligence

Avg. visit duration in Nurix Therapeutics Inc's top domains

Analyze Nurix Therapeutics Inc engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

nurixtx.com00:00:36

See more with Sales Intelligence

Avg. pageviews on Nurix Therapeutics Inc's top domains

See how Nurix Therapeutics Inc keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

nurixtx.com1.55

See more with Sales Intelligence

Nurix Therapeutics Inc top competitors by domain

Top similar sites in November 2025, ranked by their affinity

astellasgenetherapies.comCompany NameAstellas Gene TherapiesEmployees201 - 500HQUnited States, California, San FranciscoAnnual revenue$75M - $100MTotal visits369Health > Biotechnology and Pharmaceuticals

Top technologies used by Nurix Therapeutics Inc

These are the website technologies, by industry, used by Nurix Therapeutics Inc top domains

Widget (6)

Twemoji

Content Management System (3)

WordPress

Conversion & Analytics (2)

Google Analytics

eCommerce (2)

XPO Logistics

More Technologies

11

See all

News & Signals from Nurix Therapeutics Inc

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNurix, Inc. hired Roger Dansey as board of directors on Nov 10th '25.SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) - Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors.

NewsNurix, Inc. attended event 67th American Society of Hematology (ASH) Annual Meeting on Nov 3rd '25.Nurix Therapeutics announces presentations at the 67th American Society of Hematology (ASH) Annual Meeting.

NewsNurix, Inc. receives financing of $250M in registered offering.Nurix Therapeutics announces closing of $250.0 million registered offering of common stock.